The purpose of this study is to evaluate the safety and effectiveness of the WEB Embolization System, a device developed and manufactured by Sequent Medical, Inc. This device is being evaluated for use in the treatment of patients with certain types of intracranial aneurysms (IA).
In order to participate you must meet the following criteria:
- Be 18-75 years of age at the time of screening.
- Have a single ruptured or unruptured IA requiring treatment. If the subject has an additional IA requiring treatment, the additional IA must not require treatment within 60 days of the index procedure.
You will be excluded from the study if you have an IA with characteristics unsuitable for endovascular treatment.
This is a partial list of elgibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.